Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool
NCT ID: NCT06381999
Last Updated: 2024-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
73 participants
OBSERVATIONAL
2023-10-27
2024-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Spasticity Measurement Tool
NCT05374174
Effects of Selective Dorsal Rhizotomy on Non-ambulant Children With Bilateral Spastic Cerebral Palsy
NCT05006144
The Effect of Selective Dorsal Rhizotomy on a Multidimensional Outcome Set in Children With Spastic Cerebral Palsy: a Retrospective Study
NCT06340425
Physiotherapy in Hereditary Spastic Paraplegia
NCT03961906
Predictors Factors and Time of Onset of Spasticity and Their Relationship With the Functionality and Quality of Life.
NCT03459066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18-80 years old
* Preserved insight and judgment capacity
* Adequate language and task comprehension, attention span for 15 minutes
Exclusion Criteria
* Participants who received BoNT-A treatment \< 3 months before inclusion
* Reduced vigilance and attention span (less than 15 minutes)
* Participants with adult representation
* Participants with severe language impairment / impairment of movement and action sequences
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merz Therapeutics GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merz Medical Expert
Role: STUDY_DIRECTOR
Merz Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gailtal-Klinik
Hermagor, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M602011083
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.